TB advocates encourage the Global Antimicrobial Resistance Innovation Fund to prioritize research and development for drug-resistant TB.
In an open letter sent to the Global Antimicrobial Resistance Innovation Fund on 19 December 2016, TB advocates congratulated the Fund on its commitment to invest an additional £50 million over the next five years in research and development to combat antimicrobial resistance (AMR), and encouraged the Fund to prioritize drug-resistant TB in its efforts.
Drug-resistant TB is the leading cause of AMR-related deaths - causing one in three. “ … tackling TB and drug‐resistant TB must be at the heart of any global action against AMR.”
The signatories requested a response by 16 January 2017.
To read the full letter, click here.